Relay Therapeutics upgraded to Outperform: zovegalisib PI3Kα breast cancer catalyst, $596M cash to 2029, Phase 3 mid-2026.
The Chronicle is polling its readers every week via @thedukechronicle on Instagram to spotlight one Blue Devil athlete. Blue Devil of the Week returns for the spring semester to honor Duke swim and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results